SLC5A2 and type 2 diabetes mellitus: Interestingly, a recent observational study reported that patients with type 2 diabetes mellitus who were using SGLT2 inhibitors prior to the onset of myocardial infarction had a significantly lower rate of in-hospital VAs after myocardial infarction than those who were not using SGLT2 inhibitors (50).